Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of CAN008 with temozolomide during and after radiotherapy in newly diagnosed glioblastoma
CTR20211888Phase 2Active
- Sponsor
- CANbridge Pharmaceuticals Inc.
- Start
- Oct 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of asunercept in glioblastoma (GBM), sponsored by CANbridge Pharmaceuticals Inc.. Started Oct 2021; status: active.
02
Drugs
asunercept
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on CTR20211888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211888.